Calendario›IVVD›VYD2311-SD · DECLARATION

VYD2311-SD · DECLARATION

Study of VYD2311 for the Prevention of COVID-19

Ensayo de Invivyd, Inc. en COVID-19.

Más ensayos de: COVID-19.

Fase

Fase 3

Estado

En marcha, sin reclutar

Participantes

1.770

previstos

Centros

20

Fin del objetivo primario

ago 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en ene 2026.

Qué mide

COVID-19 sintomático confirmado por RT-PCR hasta el día 90 (90 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study. This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.

Más ensayos de IVVD

Todos los de IVVD, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07298434), actualizada en jun 2026.